Praxis Precision Medicines (NASDAQ:PRAX) Stock Purchase Disclosed by Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX). In a filing disclosed on October 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Praxis Precision Medicines stock on September 29th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Benchmark Electronics (NYSE:BHE) on 10/1/2026.
• Sold $1,001 – $15,000 in shares of Oxford Industries (NYSE:OXM) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of Semtech (NASDAQ:SMTC) on 9/29/2026.
• Sold $15,001 – $50,000 in shares of ITT (NYSE:ITT) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Tandem Diabetes Care (NASDAQ:TNDM) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Cytokinetics (NASDAQ:CYTK) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of YETI (NYSE:YETI) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of AtriCure (NASDAQ:ATRC) on 9/29/2026.

Praxis Precision Medicines Stock Down 3.2%

Shares of NASDAQ PRAX opened at $243.34 on Wednesday. The firm has a market cap of $6.79 billion, a price-to-earnings ratio of -18.82 and a beta of 2.79. The company’s 50-day simple moving average is $328.11 and its 200-day simple moving average is $319.59. Praxis Precision Medicines, Inc. has a 52-week low of $50.56 and a 52-week high of $392.70.

Praxis Precision Medicines (NASDAQ:PRAX) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($2.87) EPS for the quarter, topping the consensus estimate of ($3.67) by $0.80. Equities research analysts anticipate that Praxis Precision Medicines, Inc. will post -13.90 EPS for the current fiscal year.

Institutional Investors Weigh In On Praxis Precision Medicines

Institutional investors have recently added to or reduced their stakes in the business. Janus Henderson Group PLC increased its stake in Praxis Precision Medicines by 6.8% in the first quarter. Janus Henderson Group PLC now owns 3,458,863 shares of the company’s stock valued at $1,113,514,000 after purchasing an additional 218,777 shares during the period. Perceptive Advisors LLC boosted its stake in shares of Praxis Precision Medicines by 2.0% during the first quarter. Perceptive Advisors LLC now owns 2,035,986 shares of the company’s stock worth $655,974,000 after buying an additional 40,000 shares during the period. Baker BROS. Advisors LP grew its holdings in shares of Praxis Precision Medicines by 63.4% during the fourth quarter. Baker BROS. Advisors LP now owns 1,126,488 shares of the company’s stock worth $332,021,000 after buying an additional 437,000 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Praxis Precision Medicines by 2.3% during the first quarter. Bank of America Corp DE now owns 534,604 shares of the company’s stock worth $172,244,000 after buying an additional 11,841 shares during the last quarter. Finally, Barclays PLC grew its holdings in shares of Praxis Precision Medicines by 592.6% during the fourth quarter. Barclays PLC now owns 530,751 shares of the company’s stock worth $156,434,000 after buying an additional 454,114 shares during the last quarter. Hedge funds and other institutional investors own 67.84% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on PRAX shares. Piper Sandler reissued an “overweight” rating on shares of Praxis Precision Medicines in a research note on Monday, July 13th. Wall Street Zen upgraded shares of Praxis Precision Medicines from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. HC Wainwright reiterated a “buy” rating and issued a $1,201.00 target price on shares of Praxis Precision Medicines in a report on Tuesday, October 6th. BTIG Research boosted their target price on Praxis Precision Medicines from $810.00 to $826.00 and gave the company a “buy” rating in a research report on Tuesday, October 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Praxis Precision Medicines in a research note on Monday, August 24th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $613.26.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Praxis Precision Medicines

Praxis Precision Medicines, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders. The company uses insights from human genetics, neuroscience and its Cerebrum™ platform to identify and advance medicines for conditions in which existing treatment options may be limited.

Praxis’ pipeline has included investigational treatments for epilepsies and other neurological disorders, including developmental and epileptic encephalopathies, essential tremor and movement-related conditions.